首页 正文

Cellular oncology (Dordrecht). 2019 Oct;42(5):705-715. doi: 10.1007/s13402-019-00458-8 Q14.82025

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells

ribociclib介导的原发和索拉非尼耐药人肝癌细胞抗肿瘤效应的影响因素 翻译改进

Florian P Reiter  1, Gerald Denk  1, Andreas Ziesch  1, Andrea Ofner  1, Ralf Wimmer  1, Simon Hohenester  1, Tobias S Schiergens  2, Matilde Spampatti  1, Liangtao Ye  1, Timo Itzel  3, Stefan Munker  1, Andreas Teufel  3, Alexander L Gerbes  1, Julia Mayerle  1, Enrico N De Toni  4

作者单位 +展开

作者单位

  • 1 Department of Medicine II, Liver Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany.
  • 2 Biobank of the Department of General, Visceral and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany.
  • 3 Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • 4 Department of Medicine II, Liver Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, D-81377, Munich, Germany. Enrico.deToni@med.uni-muenchen.de.
  • DOI: 10.1007/s13402-019-00458-8 PMID: 31250364

    摘要 Ai翻译

    Purpose: The cyclin-dependent kinases (CDKs) CDK4 and CDK6 are important regulators of the cell cycle and represent promising targets in cancer treatment. We aimed to investigate the relevance of CDK4/6 in the development of hepatocellular carcinoma (HCC) and the potential of ribociclib, a novel orally available CDK4/6 inhibitor, as a treatment for HCC. Method... ...点击完成人机验证后继续浏览
    Copyright © Cellular oncology (Dordrecht). 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Cellular oncology

    缩写:CELL ONCOL

    ISSN:2211-3428

    e-ISSN:2211-3436

    IF/分区:4.8/Q1

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells